1. Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients—Report of the Polish Myeloma Group. (January 2016) Authors: Usnarska-Zubkiewicz, L.; Dębski, J.; Butrym, A.; Legieć, W.; Hus, M.; Dmoszyńska, A.; Stella-Hołowiecka, B.; Zaucha, J.M.; Januszczyk, J.; Rymko, M.; Torosian, T.; Charliński, G.; Lech-Marańda, E.; Malenda, A.; Jurczyszyn, A.; Urbańska-Ryś, H.; Druzd-Sitek, A.; Błońska, D.; Urbanowicz, A.; Hołojd... Journal: Leukemia research Issue: Volume 40(2016:Jan.) Page Start: 90 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1439: IMMUNE RESPONSE TO ANTI-SARS-COV-2 MRNA VACCINES IN MULTIPLE MYELOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS. (23rd June 2022) Authors: Zaleska, J.; Kwaśnik, P.; Paziewska, M.; Purkot, J.; Szabelak, A.; Jurek, M.; Masny, N.; Dziatkiewicz, I.; Własiuk, P.; Skórka, K.; Stasiak, G.; Pronobis-Szczylik, B.; Piebiak, A.; Szymczyk, A.; Jarosz-Chudzik, K.; Bołkun, L.; Kozłowska, K.; Piszcz, J.; Subocz, E.; Hałka, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗